In-vitro Evaluation of Antithrombin and Thrombolytic Activity of Leaves Extract of Lantana camara Linn

Q3 Pharmacology, Toxicology and Pharmaceutics International Journal of Pharmaceutical Quality Assurance Pub Date : 2023-06-25 DOI:10.25258/ijpqa.14.2.03

Smita Mujbaile, D. Khobragade, Dharmenndra Mundhada

{"title":"In-vitro Evaluation of Antithrombin and Thrombolytic Activity of Leaves Extract of Lantana camara Linn","authors":"Smita Mujbaile, D. Khobragade, Dharmenndra Mundhada","doi":"10.25258/ijpqa.14.2.03","DOIUrl":null,"url":null,"abstract":"Thrombosis is possible outcomes of excessive coagulation or inhibition of anticoagulant processes. The pathophysiology of thrombosis is primarily caused by irregularities of the vascular wall, changes in blood flow, and changes in blood composition. Now a day’s, various natural antithrombotic or thrombolytic medications are used for the treatment. This study evaluated the pharmacognostical, antithrombin and thrombolytic activity of leaves extract of plant Lantana camara. The extractive value of leaves extract of plant L. camara was higher (20.58%) in methylene chloride as solvent. Total ash of plant L. camara was about 9.00% w/w. In comparison with heparin L. camara extract shown 50.10, 60.23, 62.32, 68.48 and 71.32% antithrombin activity at 10, 20, 40, 60, 80 and 100 mg/mL concentration, respectively. When different extract concentrations were added in the tubes containing blood clots, L. camara showed a good thrombolytic activity. We conclude that the leaves extract of plant L. camara shows significant antithrombin and thrombolytic activity.","PeriodicalId":14260,"journal":{"name":"International Journal of Pharmaceutical Quality Assurance","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical Quality Assurance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25258/ijpqa.14.2.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Thrombosis is possible outcomes of excessive coagulation or inhibition of anticoagulant processes. The pathophysiology of thrombosis is primarily caused by irregularities of the vascular wall, changes in blood flow, and changes in blood composition. Now a day’s, various natural antithrombotic or thrombolytic medications are used for the treatment. This study evaluated the pharmacognostical, antithrombin and thrombolytic activity of leaves extract of plant Lantana camara. The extractive value of leaves extract of plant L. camara was higher (20.58%) in methylene chloride as solvent. Total ash of plant L. camara was about 9.00% w/w. In comparison with heparin L. camara extract shown 50.10, 60.23, 62.32, 68.48 and 71.32% antithrombin activity at 10, 20, 40, 60, 80 and 100 mg/mL concentration, respectively. When different extract concentrations were added in the tubes containing blood clots, L. camara showed a good thrombolytic activity. We conclude that the leaves extract of plant L. camara shows significant antithrombin and thrombolytic activity.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

马缨丹叶提取物的体外抗血栓和溶栓活性评价

血栓形成是过度凝血或抗凝过程受到抑制的可能结果。血栓形成的病理生理学主要由血管壁的不规则性、血流的变化和血液成分的变化引起。现在一天的时间里，各种天然的抗血栓或溶栓药物被用于治疗。本研究评价了马缨丹叶提取物的生药学、抗凝血酶和溶栓活性。以二氯甲烷为溶剂，卡马拉叶提取物的萃取率较高（20.58%）。卡马拉植物的总灰分约为9.00%w/w。与肝素相比，卡马拉乳杆菌提取物在10、20、40、60、80和100 mg/mL浓度下分别显示出50.10%、60.23、62.32、68.48和71.32%的抗凝血酶活性。当在含有血栓的试管中加入不同浓度的提取物时，卡马拉乳杆菌显示出良好的溶栓活性。我们得出结论，卡马拉植物的叶提取物显示出显著的抗凝血酶和溶栓活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Pharmaceutical Quality Assurance Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE is a quarterly international journal publishing the finest peer-reviewed research in the field of Pharmaceutical Quality Assurance and Pharmaceutical Analysis on the basis of its originality, importance, disciplinary interest, timeliness, accessibility, elegance, and surprising conclusions. IJPQA also provides rapid, authoritative, insightful and arresting news and interpretation of topical and coming trends affecting science, scientists and the wider public.